Literature DB >> 20878957

Mesenchymal stromal cells from primary osteosarcoma are non-malignant and strikingly similar to their bone marrow counterparts.

Jan C Brune1, Ariane Tormin, Maria C Johansson, Pehr Rissler, Otte Brosjö, Richard Löfvenberg, Fredrik Vult von Steyern, Fredrik Mertens, Anders Rydholm, Stefan Scheding.   

Abstract

Mesenchymal stromal cells (MSC) are multipotent cells that can be isolated from a number of human tissues. In cancer, MSC have been implicated with tumor growth, invasion, metastasis, drug resistance and were even suggested as possible tumor-initiating cells in osteosarcoma (OS). However, MSC from OS and their possible tumor origin have not yet been thoroughly investigated. Therefore, primary OS mesenchymal progenitors and OS-derived MSC were studied. OS samples contained very high frequencies of mesenchymal progenitor cells as measured by the colony-forming unit fibroblast (CFU-F) assay (median: 1,117 colonies per 10(5) cells, range: 133-3,000, n = 6). This is considerably higher compared to other human tissues such as normal bone marrow (BM) (1.3 ± 0.2 colonies per 10(5) cells, n = 8). OS-derived MSC (OS-MSC) showed normal MSC morphology and expressed the typical MSC surface marker profile (CD105/CD73/CD90/CD44/HLA-classI/CD166 positive, CD45/CD34/CD14/CD19/HLA-DR/CD31 negative). Furthermore, all OS-MSC samples could be differentiated into the osteogenic lineage, and all but one sample into adipocytes and chondrocytes. Genetic analysis of OS-MSC as well as OS-derived spheres showed no tumor-related chromosomal aberrations. OS-MSC expression of markers related to tumor-associated fibroblasts (fibroblast surface protein, alpha-smooth muscle actin, vimentin) was comparable to BM-MSC and OS-MSC growth was considerably affected by tyrosine kinase inhibitors. Taken together, our results demonstrate that normal, non-malignant mesenchymal stroma cells are isolated from OS when MSC culture techniques are applied. OS-MSC represent a major constituent of the tumor microenvironment, and they share many properties with BM-derived MSC.
Copyright © 2010 UICC.

Entities:  

Mesh:

Year:  2010        PMID: 20878957     DOI: 10.1002/ijc.25697

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  29 in total

1.  Osteogenic differentiation of CD271(+) cells from rabbit bone marrow cultured on three phase PCL/TZ-HA bioactive scaffolds: comparative study with mesenchymal stem cells (MSCs).

Authors:  Alessia Colosimo; Cristina Rofani; Elisa Ciraci; Aurelio Salerno; Maria Oliviero; Ernesto Di Maio; Salvatore Iannace; Paolo A Netti; Francesco Velardi; Anna C Berardi
Journal:  Int J Clin Exp Med       Date:  2015-08-15

Review 2.  Bone microenvironment signals in osteosarcoma development.

Authors:  Arantzazu Alfranca; Lucia Martinez-Cruzado; Juan Tornin; Ander Abarrategi; Teresa Amaral; Enrique de Alava; Pablo Menendez; Javier Garcia-Castro; Rene Rodriguez
Journal:  Cell Mol Life Sci       Date:  2015-05-03       Impact factor: 9.261

Review 3.  Mesenchymal Stem Cell-derived Extracellular Vesicles: Toward Cell-free Therapeutic Applications.

Authors:  Sweta Rani; Aideen E Ryan; Matthew D Griffin; Thomas Ritter
Journal:  Mol Ther       Date:  2015-03-19       Impact factor: 11.454

4.  A novel cell-free strategy for promoting mouse liver regeneration: utilization of a conditioned medium from adipose-derived stem cells.

Authors:  Sang Kuon Lee; Sang Chul Lee; Say-June Kim
Journal:  Hepatol Int       Date:  2014-12-25       Impact factor: 6.047

5.  Cancer-associated mesenchymal stroma fosters the stemness of osteosarcoma cells in response to intratumoral acidosis via NF-κB activation.

Authors:  Sofia Avnet; Gemma Di Pompo; Tokuhiro Chano; Costantino Errani; Arig Ibrahim-Hashim; Robert J Gillies; Davide Maria Donati; Nicola Baldini
Journal:  Int J Cancer       Date:  2017-03-15       Impact factor: 7.396

Review 6.  Perspectives on cancer stem cells in osteosarcoma.

Authors:  Upal Basu-Roy; Claudio Basilico; Alka Mansukhani
Journal:  Cancer Lett       Date:  2012-05-29       Impact factor: 8.679

7.  Effect of mesenchymal stem cells on hypoxia-induced desensitization of β2-adrenergic receptors in rat osteosarcoma cells.

Authors:  Akira Kido; Kazuhiro Yoshitani; Takamasa Shimizu; Manabu Akahane; Hiromasa Fujii; Shinji Tsukamoto; Yumiko Kondo; Kanya Honoki; Motohiro Imano; Yasuhito Tanaka
Journal:  Oncol Lett       Date:  2012-07-19       Impact factor: 2.967

8.  Shared cell surface marker expression in mesenchymal stem cells and adult sarcomas.

Authors:  Stefan Wirths; Elke Malenke; Torsten Kluba; Simone Rieger; Martin R Müller; Sabine Schleicher; Claus Hann von Weyhern; Florian Nagl; Falko Fend; Wichard Vogel; Frank Mayer; Lothar Kanz; Hans-Jörg Bühring; Hans-Georg Kopp
Journal:  Stem Cells Transl Med       Date:  2012-12-19       Impact factor: 6.940

Review 9.  Multipotent mesenchymal stromal cell therapy and risk of malignancies.

Authors:  Federica Casiraghi; Giuseppe Remuzzi; Mauro Abbate; Norberto Perico
Journal:  Stem Cell Rev Rep       Date:  2013-02       Impact factor: 5.739

Review 10.  Stem cells and bone diseases: new tools, new perspective.

Authors:  Mara Riminucci; Cristina Remoli; Pamela G Robey; Paolo Bianco
Journal:  Bone       Date:  2014-09-18       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.